|
Toxin Working Group of the Intragovernmental Select Agents and Toxins Technical Advisory Committee (ISATTAC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NIAID
|
The workgroup holds biweekly meetings to discuss the following: point of regulation of select toxins (Botulinum neurotoxins, Staphylococcal enterotoxins, Abrin, Ricin, Conotoxins, Saxitoxin, Tetrodotoxin, Diacetoxyscirpenol, T-2 toxin), natural environment, toxin exclusion limits, space decontamination, and potential updates to the Centers for Disease Control and Prevention (CDC) manual “Biosafety in Microbiological and Biomedical Laboratories.”
|
|
Toxins Assessment Working Group
|
Committee, Work group, Advisory group, or Task Force
|
ASPR, CDC, FDA
|
NIAID
|
Biological (not engineered) toxins with specific effects on the nervous system, focusing on neurotoxins, applications in medical research and historical consideration as bioweapons
|
|
Tracking Resistance and Coronavirus Evolution (TRACE)
|
Resource Development
|
ASPR, CDC, FDA
|
NCATS, NIAID
|
The ACTIV Tracking Resistance and Coronavirus Evolution (TRACE) initiative is focused on identifying emerging variants of SARS-CoV-2, the coronavirus that causes COVID-19 disease. The initiative is surveying new viral variants, assessing vaccine and therapeutic resistance, and evaluating the impact of genetic variation on viral biology and on the clinical approaches for preventing and treating illness. TRACE ;aims to prioritize which viral variants should be studied to determine the effectiveness of vaccines and therapeutics currently in late stages of development against these variants; coordinate data sharing; and confirm testing and periodic (e.g. weekly) public reporting of results to allow confident decision making by the U.S. Government (USG), health professionals, and pharmaceutical organizations. The initiative, which is being led by NIH and facilitated by the Foundation for the National Institutes of Health, with participation by the ACTIV public-private partners, is developing the infrastructure and processes for monitoring and testing emerging SARS-CoV-2 variants and standardizing, gathering, and sharing variant sequencing data.;
|
|
Training Advisory Committee (TAC)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ
|
OD/OER, CSR, FIC, NCATS, NCCIH, NCI, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/ORIP
|
The Training Advisory Committee (TAC) advises on programmatic, review, and management issues related to extramural research training, research education, career development and diversity programs and the Loan Repayment Programs (LRP), and evaluation of these programs. TAC provides a trans-NIH forum to identify and discuss issues related to these programs and recommend solutions.
|
|
Trans-Agency (Medical) Imaging Phantom (TAIP) Workgroup
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCI, NIBIB
|
A common set of scientifically validated medical phantoms that have long term curation, convenient dissemination, associated measurement protocols and analysis software, will be of great benefit to the ;FDA, NIH, NIST and to the scientific community they serve. ;;This;woring group is;created to enhance collaborationt between FDA, NIST, and NIH to cooperate, where possible, on the development, validation, and dissemination of these medical calibration objects and to maintain at library of these medical phantoms for use by the larger medical community.
|
|
Trans-Agency Meeting on Adult Obesity Treatment and Prevention: State of the Science, Research Gaps, and Opportunities for Furture Research
|
Meeting/ Workshop
|
AHRQ, CDC, HRSA, OASH
|
NHLBI, NCI, NIDDK, NIAMS, NCCIH, NIMHD, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP, OD/DPCPSI/OPA
|
The Trans-Agency Meeting on Adult Obesity Treatment and Prevention: State of the Science, Research Gaps and Opportunities for Future Research was held virtually on September 16 and 24, 2021. The purpose of this meeting was to bring together key staff from NIH and other federal and non-governmental organizations to discuss the current state of adult obesity prevention and treatment research, knowledge gaps, and opportunities for future research and directions. The meeting was attended by 58 participants across 20 NIH Institutes, Centers or Offices (ICOs), five (5) other federal agencies, and two (2) non-governmental organizations (NGOs). The meeting laid the groundwork for a future workshop on this topic and other trans-agency activities in FY 2022 and beyond. The federal agencies represented at this meeting included NIH, HHS Health Resources and Services Administration (HRSA), HHS Office of the Assistant Secretary for Health (OASH), Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control (CDC), and the Veterans Health Administration (VA). ;
|
|
Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, ASPR
|
NIAID
|
The presidential declaration issued at the 2009 EU-US summit called for the creation of “a transatlantic task force on urgent antimicrobial resistance issues focused on appropriate therapeutic use of antimicrobial drugs in the medical and veterinary communities, prevention of both healthcare- and community-associated drug-resistant infections, and strategies for improving the pipeline of new antimicrobial drugs, which could be better addressed by intensified cooperation between us.” The objectives of the Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR) are to increase the mutual understanding of US and EU activities and programs relevant to the antimicrobial resistance issues identified in the declaration in order to deepen the transatlantic dialogue, provide opportunities to learn from each other, and promote information exchange, coordination, and cooperation.
|
|
Trans-HHS program for Multi-System Inflammatory Syndrome in Children (MIS-C) and pediatric SARS-CoV-2 (CARING)
|
Research Initiative
|
CDC, FDA, OASH
|
NHLBI
|
Staff from NHLBI and NICHD, the NIH co-leads, as well as NIAID collaborate with the Office of the Assistant Secretary of Health, CDC, and the FDA to guide a federal research program for MIS-C and pediatric SARS-CoV-2.
|
|
Trans-NIH Liver Cancer Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NCI, NIDDK, NIAAA, NIAID
|
The charge of this working group is to develop an integrated NIH-wide plan for research in liver cancer that addresses basic, behavioral, translational, and clinical aspects of liver cancer aimed at understanding the basic mechanisms, the prevention, and cure of the disease. Additionally, the working group is interested in global health and health disparities research on liver disease.
|
|
Trans-NIH Structural Birth Defects Working Group (SBDWG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NICHD, NCI, NEI, NHGRI, NHLBI, NIAAA, NIAMS, NIDCD, NIDCR, NIDDK, NIEHS, NINDS
|
The Trans-NIH SBDWG brings together extramural program officials from NIH components whose missions include research into structural birth defects, with the ultimate goal of facilitating advances in our understanding of the etiology, mechanisms, epidemiology, prevention, and treatment of structural birth defects.
|